alexa Bio-similars, Neoterics Of Pharmaceuticals
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars
October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Kalakonda Sri Nataraj
Accepted Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.015
Pharmaceutical industry has always been the most bread neck for transformation in the field of research and healthcare. The evolution of medicines from the traditional leaf extracts to swinging Liposome's, human insulin preparations, delayed release and modified release formulations & multilayered multi tablets is promising and riveting. However, growing aging population, chronic diseases around the globe and synchronic rise in the demand for spanking quality in healthcare has brought the need to develop products called Biosimilars. Biosimilars are on the whole a new class of biologic drugs which are similar to the generics but not identical. They are state of art designer molecules derived from living organisms. WHO defines Biosimilars as ?A bio therapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference bio therapeutic product?. Over the next few years, generic drugs worth an estimated $81 billion in global annual sales, and biologics worth 20 billion $ will lose their patents by 2015. Globally Biosimilars market is predicted to grow by US $19.4 billion in 2014. By then, fusion proteins and monoclonal antibodies used in cancer and autoimmune diseases are expected to form a substantial proportion of this new line of biosimilars. Biosimilars are advantageous over biologics in saving costs and expenditures on the whole lot of departments like developing, manufacturing, analytical testing and marketing of the products. Regulatory agencies like WHO, USFDA and EMA are developing laws and standards to develop spanking quality of products to the healthcare world. The transformation from biologics to biosimilars is going to dawn a new generation of medicines using advanced techniques in the field of treatments. India and south central Asia are going to be the hub for this new generation neoterics in pharmaceuticals.
Kalakonda Sri Nataraj has completed his PhD at the age of 35 years from JNTUA University. He is the Professor of Shri Vishnu College of Pharmacy, accredited by NBA & NAAC. He has published more than 32 papers in reputed journals and serving as an Editorial Board Member of repute and recently sanctioned the project from DST under young scientist scheme.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version